Adamas Pharmaceuticals Inc said on Tuesday its drug to treat walking impairment in patients with Multiple Sclerosis did not show the clinical benefit the drugmaker was hoping for in a late-stage trial.Reuters Health Information (Source: Medscape Allergy Headlines)

Read full article on

Powered by Preisvergleich RSS Statement

Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.